TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine Injection and Ischemic Compression on Chronic Pelvic Pain Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with chronic diagnosis of pelvic pain;~2. Women in menacme;~3. Presence of the diagnostic criteria for abdominal myofascial syndrome;~4. Agreement with the Term of Free and Clarified Assent.~Exclusion Criteria:~1. Endometriosis, interstitial cystitis, syndrome of the irritable intestine or another illness that it justifies or it contributes for chronic pelvic pain;~2. Endometrioma or hernia evidenced to the ultrasound of the abdominal wall.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- lidocaine injection (Type: EXPERIMENTAL): Lidocaine injection. Women randomized for this treatment was submitted to 2 milliliters of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point.~Patients received lidocaine injections once a week for 4 weeks
- Ischemic compression (Type: EXPERIMENTAL): Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation (TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with tumors of the head and neck region (nasal cavity, oral cavity, pharynx, larynx, sinuses, salivary glands, and head and neck skin) who are candidates for radiation treatment.~Exclusion Criteria:~* Contraindications for MRI: All patients will be screened with standard UWHC MRI screening procedures:~* Any person with the following will be excluded: cardiac pacemaker, metal fragments in or around the eye, venous umbrella, permanent eyeliner or permanent artificial eyebrows.~Patents with the following potentially non-MRI compatible devices will undergo screening using the standard UWHC MRI screening protocol by trained UWHC personnel: cardiac pacemaker, heart valve replacement, intracranial aneurysm clips, middle ear, eye, joint, or penile implants, joint replacements, implantable hearing aids, neurostimulator devices, insulin pumps, shunts/stents, metal mesh/coil implants; metal plate/pin/screws/wires, or any other metallic implants. Also patients with anatomical constraints limiting the feasibility of MRI will be excluded.~- Issue of pregnancy: We will exclude all known pregnant females from the study to avoid the potential risk of fetal injury upon exposure to the PET scan. Determination of pregnancy will be based upon the standard screening procedures in place for radiation therapy.~* Persons who are not fluent in English~* Anyone who can not provide written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET/MRI (Type: None): All participants will undergo a diagnostic PET/CT and a Radiation Treatment Planning CT per SOC procedures. In addition, all participants will undergo an additional imaging set consisting of a PET/MRI. It is anticipated that most patients will undergo the PET/MRI on the same day as their PET/CT negating the need for a second injection of the FDG radioisotope used for SOC PET imaging. All participants will receive gadolinium contrast per SOC dosing guidelines for the MRI portion of the PET/MRI. Both SOC MMRI pulse sequences and investigational sequences will be utilized in this study.~If a second dose of the radioisotope is need to complete the PET/MRI (unable to perform both PET scans on the same day) only a 50% dose of FDG will be administered due to the increased sensitivity the PET/MRI scanner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive and Invasive Assessment of Coronary Artery Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with stable angina pectoris with low to intermediate pre-test likelihood of CAD;~2. no previous history of CAD;~3. obstructive stenosis (≥50% luminal narrowing) on MSCT coronary angiography; 4.informed consent.~Exclusion Criteria:~1. patients with a previous history of CAD;~2. patients with contraindications for MSCT: a.cardiac rhythms other than sinus rhythm, b.pregnancy, c.allergy for contrast medium, d.renal failure (estimated glomerular filtration rate (eGFR) \< 50ml/min), e.resting heart rate \>75 bpm plus contra-indications for beta-blockade, f. weight \>100 kilograms;~3. contraindications for cardiac magnetic resonance (CMR) imaging: a.MR-incompatible implants, b. Claustrophobia, c. contraindications for adenosine: i. known or suspected hypersensitivity to adenosine, ii. known or suspected bronchoconstrictive or bronchospastic disease, iii. 2nd or 3rd degree atrioventricular (AV) block, iv. Sinus bradycardia (heart rate \< 45 bpm), v. Systemic arterial hypotension (\<90 mmHg). d. contraindications for gadolinium: i. renal failure (estimated eGFR \<30 ml/min);~4. no informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imaging arm (Type: OTHER): There is one study arm only. The imaging modalities will be performed in all patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of Megadose Shinbaro Pharmacopuncture for Patients With Chronic Shoulder Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with NRS ≥ 4 for shoulder pain over 3weeks~* Patients aged 19-70 years on the date they sign the consent form.~* Patients who provide consent to participate in the trial and return the informed consent form~Exclusion Criteria:~* Patients who have been diagnosed with a severe disease that may cause shoulder pain,~* Patients with progressive neurological deficit or with serious neurological symptoms caused by spinal cord compression.~* Patients who visited a hospital in pain caused by a traffic accident.~* Patients with a severe mental illness.~* Patients who are difficult to complete the research participation agreement

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Megadose Shinbaro Pharmacopuncture Group (Type: None): The Megadose Shinbaro Pharmacopuncture group who are treated with korean medical treatment including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine.
- Control Group (Type: None): The control group who are treated with Korean medical treatment not including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Abrupt Versus Tapered Interruption of Chronic Clopidogrel Therapy After DES Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with planned interruption of chronic clopidogrel therapy after DES implantation~* Informed, written consent by the patient~Exclusion Criteria:~* Planned surgery within the next month~* Active bleeding as reason for clopidogrel discontinuation~* Concomitant coumadin therapy~* Pregnancy (present, suspected or planned) or positive pregnancy test (In women with childbearing potential a negative pregnancy test is mandatory)~* Malignancies or other comorbid conditions with a life expectancy of less than one year or that may result in protocol noncompliance.~* Patient's inability to fully comply with the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clopidogrel Tapering (Type: ACTIVE_COMPARATOR): None
- Abrupt Clopidogrel Interruption (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Intake During Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active Duty and Department of Defense (DoD) beneficiary Pregnant women 18 years of age and older~* 37 weeks gestation or greater at time of admission~* singleton fetus~* cephalic presentation~* who plan to labor/deliver at DGMC (military beneficiaries).~Exclusion Criteria:~* Morbid/severe obesity (pre-pregnancy BMI ≥40 kg/m2~* diabetes~* hypertension (to include pre-eclampsia or eclampsia)~* previous cesarean section~* uncontrolled gastroesophageal reflux disease (GERD) (symptomatic with medication)~* past history or current diagnosis of hyperemesis gravidarum~* food allergies to any items contained in the gastric/soft bland diet~* patients utilizing nitrous oxide for labor analgesia (should this treatment be available at DGMC)~* Difficult airway as defined by the anesthesia staff.~* Mallampati score 3 or 4~* Thyroid mental distance less than 7 cm or 3 finger breaths~* Mouth opening less than 3 finger breaths~* Short thick neck, Micrognathia~* Further indications as determined by the anesthesia provider doing the anesthesia preoperative assessment (pregnancy in and of itself will not be considered a disqualification due to airway changes during labor) in order to define difficult airway per anesthesia.~* Under age 18~* Additional clinical risk factors as determined by the care provider

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): Routine care during labor (authorized clear liquid diet).
- Experimental Group (Type: ACTIVE_COMPARATOR): Patients in the experimental group will have a gastric soft/bland diet available, which will include lean protein, fruits, vegetables, and low-fat dairy. This will be ordered in the electronic medical record (EMR) and is a standard non-select meal, referred to as a gastric/soft bland diet that is not based on patient's preferred menu selections.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Empagliflozin in NODAT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Single kidney transplantation~* Normal glucose tolerance or Pre-Diabetes mellitus before transplantation~* According to Oral glucose tolerance test results to make the diagnosis of NODAT~* Standard triple immunosuppression therapy~* HbA1c≤10%~* Steady hormone usage~* BMI 18.5-30kg/m2~* Patient informed consent~Exclusion Criteria:~* Diabetes patients before transplantation~* Pregnancy pregnancy~* Type 1 diabetes after kidney transplantation~* Severe liver function impairment (AST/ALT 3 times standard value)~* Severely impaired renal function (eGFR\<45)~* Having uncontrolled diseases~* History of cancer in the past 5 years (except basal cell carcinoma) and/or cancer treatment~* Participating in another trial involving the study drug with in 30 days~* Premenopausal women (1 year before the last menstrual period ≤ informed consent)~* Alcohol or drug abuse within 3 months of informed consent, affecting compliance Need other drugs to control NODAT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: ACTIVE_COMPARATOR): Jardiance 10mg/25mg Film-coated tablets， once daily
- Linagliptin (Type: ACTIVE_COMPARATOR): Trajenta 5mg Film-coated tablets， once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Function Following Partial and Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients that have elected to undergo either partial or total knee replacement, as well as a control group of patients free of lower extremity pathology~Exclusion Criteria:~* Sensory, neurological, or general health conditions that alter perception of the patient's limb in space~* Vestibular disorders will be excluded in order to protect against falls during functional testing~* Unable to understand the questions used to obtain the Knee Society Score~* Minors and prisoners will be excluded from the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Patients undergoing total knee replacement
- 2 (Type: NO_INTERVENTION): Healthy volunteers that are not undergoing knee replacement surgery
- 3 (Type: EXPERIMENTAL): Patients undergoing partial knee replacement with the Oxford mobile bearing implant system
- 4 (Type: EXPERIMENTAL): Patients undergoing partial knee replacement with the Vanguard M implant system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG performance status of ≤2.~* Relapsed or refractory disease to at least one prior systemic regimen.~* Measurable disease: according to International Working Group (IWG) guidelines for all patients with PTCL and according to CTCL Response in Skin consensus criteria for all patients with CTCL.~* Objective, documented evidence of disease progression on study entry.~Exclusion Criteria:~* Known active central nervous system (CNS) lymphoma.~* Active graft-versus-host disease after allogeneic stem cell transplantation. At least 4 months must have elapsed since completion of allogeneic stem cell transplantation.~* Unable to swallow tablets or malabsorption syndrome, disease significantly affecting gastrointestinal function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Selinexor (Type: EXPERIMENTAL): 60 mg dose (equivalent to \~35 mg/m²)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent must be obtained before any assessment is performed.~2. Subjects that either discontinue prematurely or complete the CLCQ908B2302 study after 52 weeks or FCS subjects who have previously completed study CLCQ908A2212.~Exclusion Criteria:~1. Subjects discontinued from the CLCQ908B2302 study for serious, potentially study drug related adverse events.~2. Subjects from the CLCQ908B2302 study who have developed any other contraindication to participation (for example, renal failure)~3. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~4. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.~5. Subjects with type 1 diabetes mellitus or type 2 diabetes mellitus if HbA1C is ≥ 8.5%.~6. Treatment with fish oil preparations within 4 weeks prior to randomization.~7. Treatment with bile acid binding resins (i.e., colesevelam, etc) within 4 weeks prior to randomization.~8. Treatment with fibrates within 8 weeks prior to randomization. Washout may occur following screening if required.~9. Glybera \[alipogene tiparvovec (AAV1-LPLS447X )\] gene therapy exposure within the two years prior to screening.~10. eGFR \<45 ml/min/1.73m2 or history of chronic renal disease.~Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCQ908 (Type: EXPERIMENTAL): Patients initiated at 10 mg/day. After at least 8 weeks of treatment with a dose, optional up-titration to the next possible dose will be allowed. One down titration allowed from the highest dose attained.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Resolution Endoclips Vs Epinephrine Injection and Heater Probe

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>16 , can obtain written consent~* Ulcers that require endoscopic therapy with SRH: Forrest I a, Ib, II a and II b~Exclusion Criteria:~* Moribund patients with terminal malignancy~* Pregnancy~* Intercurrent ulcer complication that prevents treatment and surgery becomes mandatory such as bulbar stenosis and ulcer perforation

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DUAL THERAPY (Type: NO_INTERVENTION): DUAL THERAPY
- 'Resolution clip (Type: EXPERIMENTAL): 'Resolution clip

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Regular smokers (currently \>10 cigarettes/day; \>5 pack years)~* Willing to quit smoking for at least the duration of the study~* Able and willing to give written informed consent~Exclusion Criteria:~* Known condition causing endothelial dysfunction except smoking (i.e. diabetes, hyperlipi¬demia, arterial hypertension, obesity)~* Regular drug treatment and/or sporadic consumption of drugs within the last 4 weeks (exclusion has to be decided in each individual)~* Acute or chronic illness~* Participation in clinical trial within 1 month before the study~* Excessive daily intake of alcohol (\>2 servings per day) or caffeine (\>4 servings/day)~* Drug and/or alcohol abuse.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Varenicline (Type: ACTIVE_COMPARATOR): Participants on this arm will receive varenicline tablets for 15 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants on this arm will receive placebo tablets for 15 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues